REFERENCES

1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34(11):1803–5.

2. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–33.

3. United States Renal Data System. 2020 USRDS annual data report: epidemiology of kidney disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD [updated, 2020]. https://adr.usrds.org/2020. Accessed 6 Dec 2021.

4. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;3(1):1–150. 214 Adv Ther (2022) 39:193–220

5. Elshahat S, Cockwell P, Maxwell AP, Griffin M, O’Brien T, O’Neill C. The impact of chronic kidney disease on developed countries from a health eco￾nomics perspective: a systematic scoping review. PLoS One. 2020;15(3):e0230512.

6. Cooper JT, Lloyd A, Sanchez JJG, Sorstadius E, Briggs A, McFarlane P. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a sys￾tematic literature review. Health Qual Life Out￾comes. 2020;18(1):310.

7. Olufade T, Lamerato L, Sanchez JJG, et al. Clinical outcomes and healthcare resource utilization in a real-world population reflecting the DAPA-CKD trial participants. Adv Ther. 2021;38:1352–63.

8. Darlington O, Dickerson C, Evans M, et al. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney disease: evidence from a systematic litera￾ture review. Adv Ther. 2021;38:994–1010.

9. Murton M, Goff-Leggett D, Bobrowska A, et al. Burden of chronic kidney disease by KDIGO cate￾gories of glomerular filtration rate and albuminuria: a systematic review. Adv Ther. 2021;38(1):180–200.

10. Perkovic V, Craig JC, Chailimpamontree W, et al. Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney Int Suppl. 2017;7(2):138–44.

11. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–54.

12. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099.

13. Zinman B, Wanner C, Lachin JM, et al. Empagli- flozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22): 2117–28.

14. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

15. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Out￾comes in New Users of Sodium-Glucose Cotrans￾porter-2 Inhibitors). Circulation. 2017;136(3): 249–59.

16. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

17. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020. https://doi.org/10. 1056/NEJMoa1911303.

18. Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: Wiley; 2019.

19. Centre for Reviews Dissemination. Systematic reviews. York: CRD, York Publishing Services Ltd; 2009.

20. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 London. https://www.ncbi.nlm.nih.gov/pubmed/ 27905712. Accessed 6 Dec 2021.

21. Scottish Intercollegiate Guidelines Network. Search filters. https://www.sign.ac.uk/what-we-do/ methodology/search-filters/. Accessed 6 Dec 2021.

22. Cochrane. Embase: Cochrane. https://work. cochrane.org/embase. Accessed 4 Nov 2020.

23. Halfpenny NJA, Scott DA, Thompson JC, Gurung B, Quigley JM. A practical approach to predict expan￾sion of evidence networks: a case study in treat￾ment-naive advanced melanoma. Melanoma Res. 2019;29(1):13–8.

24. National Institute for Health and Care Excellence. Single technology appraisal: user guide for com￾pany evidence submission template. Process and methods [PMG24] 2017. https://www.nice.org.uk/ process/pmg24/chapter/instructions-for￾companies. Accessed 6 Dec 2021.

25. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.

26. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23): 2219–29.

27. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24): 2295–306.

28. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal out￾comes in type 2 diabetes mellitus and chronic kid￾ney disease in primary and secondary Adv Ther (2022) 39:193–220 215 cardiovascular prevention groups. Circulation. 2019;140(9):739–50.

29. Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31(5):1128–39.

30. Liu M, Li F, Liang M, Rao X. Effects of aldose reductase inhibitors on renal blood flow parameters in patients with early diabetic nephropathy. J Dia￾betes Complications. 2020;34(9):107620.

31. Yagoglu AI, Dizdar OS, Erdem S, Akcakaya B, Gunal AI. The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kid￾ney disease: a prospective randomized controlled study. Nefrologia. 2020;40(6):664–71.

32. Allegretti AS, Zhang W, Zhou W, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019;74(3):328–37.

33. Pollock C, Stefansson B, Reyner D, et al. Albumin￾uria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapa￾gliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocri￾nol. 2019;7(6):429–41.

34. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high car￾diovascular and renal risk: the CARMELINA ran￾domized clinical trial. JAMA. 2019;321(1):69–79.

35. Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of dapagliflozin in patients with type 2 dia￾betes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Dia￾betes Obes Metab. 2018;20(11):2532–40.

36. Grunberger G, Camp S, Johnson J, et al. Ertugli- flozin in patients with stage 3 chronic kidney dis￾ease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1): 49–66.

37. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-la￾bel, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–17.

38. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19(11):1610–9.

39. Yoon SA, Han BG, Kim SG, et al. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Kor￾ean type 2 diabetes patients with moderate to severe renal impairment: a 12-week, double-blind ran￾domized study (the GUARD Study). Diabetes Obes Metab. 2017;19(4):590–8. 40. Han SY, Yoon SA, Han BG, et al. Comparative effi- cacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: a

40-week extension of the GUARD randomized study. Diabetes Obes Metab. 2018;20(2):292–300.

41. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA￾RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222–30.

42. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidia￾betes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocri￾nol. 2014;2(5):369–84.

43. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–71.

44. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016–27.

45. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–73.

46. Shikata K, Haneda M, Ninomiya T, et al. Random￾ized trial of an intensified, multifactorial interven￾tion in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan). J Diabetes Investig. 2021;12(2):207–16.

47. Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937–47.

48. Chen Y, Liu P, Chen X, Li Y, Zhang F, Wang Y. Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion 216 Adv Ther (2022) 39:193–220 rate in elderly patients with early type 2 diabetic nephropathy. Am J Med Sci. 2018;355(5):418–24.

49. Scheele W, Diamond S, Gale J, et al. Phosphodi￾esterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. J Am Soc Nephrol. 2016;27(11):3459–68.

50. Han SJ, Kim HJ, Kim DJ, et al. Effects of pentoxi￾fylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective ran￾domized double-blind multicenter study. Diabetol Metab Syndr. 2015;7:64.

51. Navarro-Gonza´lez JF, Mora-Ferna´ndez C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015;26(1):220–9.

52. Pan Y, Qiao QY, Pan LH, et al. Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Exp Clin Endocrinol Diabetes. 2015;123(3):170–7.

53. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20): 1892–903.

54. Palevsky PM, Zhang JH, Seliger SL, Emanuele N, Fried LF, VA NEPHRON-D Study. Incidence, sever￾ity, and outcomes of AKI associated with dual renin￾angiotensin system blockade. Clin J Am Soc Nephrol. 2016;11(11):1944–53.

55. Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):131–6.

56. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 dia￾betes with overt nephropathy: a multicentre, ran￾domised, placebo-controlled study. Diabetologia. 2011;54(12):2978–86.

57. Mann JFE, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527–35.

58. Bakris G, Burgess E, Weir M, Davidai G, Koval S, AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364–9.

59. Barnett AH, Bain SC, Bouter P, et al. Angiotensin￾receptor blockade versus converting-enzyme inhi￾bition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952–61.

60. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Me´nard J. Effects of low dose ramipril on cardio￾vascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328(7438):495.

61. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.

62. Lewis EJ, Hunsicker LG, Clarke WR, et al. Reno￾protective effect of the angiotensin-receptor antag￾onist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12): 851–60.

63. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45(2):281–7.

64. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138(7):542–9.

65. Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin￾dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lan￾cet. 1997;349(9068):1787–92.

66. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–62.

67. Voroneanu L, Siriopol D, Dumea R, et al. Addition of silymarin to renin–angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial. Int Urol Nephrol. 2017;49(12):2195–204.

68. Endo K, Saiki A, Yamaguchi T, et al. Probucol sup￾presses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study. J Atheroscler Thromb. 2013;20(5):494–502.

69. Rutter MK, Prais HR, Charlton-Menys V, et al. Pro￾tection against nephropathy in diabetes with ator￾vastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose ator￾vastatin. Diabet Med. 2011;28(1):100–8.

70. Abe M, Maruyama N, Okada K, Matsumoto S, Mat￾sumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18(11):1018–28. Adv Ther (2022) 39:193–220 217

71. Endo K, Miyashita Y, Sasaki H, et al. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract. 2006;71(2):156–63.

72. Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):123–30.

73. de Zeeuw D, Akizawa T, Audhya P, et al. Bardox￾olone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369(26): 2492–503.

74. Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23): 2204–13.

75. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21): 2019–32.

76. Nakamoto H, Yu XQ, Kim S, et al. Effects of sus￾tained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Ther Apher Dial. 2020;24(1):42–55.

77. Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double￾blind trial. Circulation. 2018;138(15):1505–14.

78. Ameen, Kashif MA, Sumreen. To compare anti-al￾bumin urea effects of valsartan alone with combi￾nation of valsartan and amlodipine in patients of chronic kidney disease. Pak J Med Sci. 2016;32(3): 613–6.

79. Hosoya T, Ohno I, Nomura S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18(6):876–84.

80. Ando K, Nitta K, Rakugi H, et al. Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in renin-angiotensin system (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics TreatMent with RAS inhibitOrs in a Chronic Kidney Disease Hypertensive Population) study. Int J Med Sci. 2014;11(9):897–904.

81. Ando K, Ueshima K, Tanaka S, et al. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. Int J Med Sci. 2013;10(9):1209–16.

82. Wang W, Li L, Zhou Z, Gao J, Sun Y. Effect of spironolactone combined with angiotensin-con￾verting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Exp Ther Med. 2013;6(6):1527–31.

83. Yasuda T, Endoh M, Suzuki D, et al. Effects of val￾sartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT). Hypertens Res. 2013;36(3):240–6.

84. Abe M, Okada K, Maruyama N, et al. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res. 2011;34(2):268–73.

85. Bakris GL, Sarafidis PA, Weir MR, et al. Renal out￾comes with different fixed-dose combination ther￾apies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespeci- fied secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173–81.

86. Ruggenenti P, Perna A, Tonelli M, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol. 2010;5(11):1928–38.

87. Abe M, Okada K, Maruyama N, et al. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert Opin Investig Drugs. 2010;19(9):1027–37.

88. Iino Y, Hayashi M, Kawamura T, et al. Renoprotec￾tive effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hyper￾tension–a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res. 2004;27(1):21–30.

89. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benaze￾pril on the progression of chronic renal insuffi- ciency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939–45.

90. Maschio G, Alberti D, Locatelli F, et al. Angiotensin￾converting enzyme inhibitors and kidney protec￾tion: the AIPRI trial. The ACE Inhibition in Pro￾gressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;33(Suppl 1):S16-20 (discussion S41–3). 218 Adv Ther (2022) 39:193–220

91. Kimura G, Kasahara M, Ueshima K, et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assess￾ment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2017;21(3):417–24.

92. Suzuki H, Watanabe Y, Kumagai H, Shuto H. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther Adv Car￾diovasc Dis. 2013;7(6):306–15.

93. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784): 2181–92.

94. Haynes R, Lewis D, Emberson J, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25(8):1825–33.

95. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effect of atorvastatin on kidney func￾tion in chronic kidney disease: a randomised dou￾ble-blind placebo-controlled trial. Atherosclerosis. 2010;213(1):218–24.

96. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clin Nephrol. 2014;81(2):75–85.

97. Cha RH, Kang SW, Park CW, et al. A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol. 2016;11(4):559–67.

98. Schulman G, Berl T, Beck GJ, et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26(7):1732–46.

99. Akizawa T, Asano Y, Morita S, et al. Effect of a car￾bonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54(3):459–67.

100. Badve SV, Pascoe EM, Boudville N, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–13.

101. Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymp￾tomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798–810.

102. Goicoechea M, De Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93.

103. Tsubakihara Y, Gejyo F, Nishi S, et al. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial. 2012;16(6):529–40.

104. Wesson DE, Mathur V, Tangri N, et al. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-con￾trolled, 40-week extension. Lancet. 2019;394(10196):396–406.

105. Goicoechea M, de Vinuesa SG, Quiroga B, et al. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER study). Cardiovasc Drugs Ther. 2018;32(3):255–63.

106. Hayashi T, Maruyama S, Nangaku M, et al. Darbe￾poetin alfa in patients with advanced CKD without diabetes: randomized, controlled trial. Clin J Am Soc Nephrol. 2020;15(5):608–15.

107. Ando K, Ohtsu H, Uchida S, et al. Anti-albuminuric effect of the aldosterone blocker eplerenone in non￾diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(12):944–53.

108. Woo KT, Choong HL, Wong KS, et al. Aliskiren and losartan trial in non-diabetic chronic kidney dis￾ease. J Renin Angiotensin Aldosterone Syst. 2014;15(4):515–22.

109. Shen PC, He LQ, Yang XJ, Cao HX. Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease. J Investig Med. 2012;60(7):1041–7.

110. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis. 2010;55(4):671–81.

111. Esnault VL, Brown EA, Apetrei E, et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephro￾pathies: a 3-year, randomized, multicenter, double￾blind, placebo-controlled study. Clin Ther. 2008;30(3):482–98.

112. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18(6):1889–98. Adv Ther (2022) 39:193–220 219

113. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131–40.

114. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939–46.

115. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719–28.

116. Cinotti GA, Zucchelli PC, Collaborative Study Group. Effect of lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant. 2001;16(5):961–6.

117. Herlitz H, Harris K, Risler T, et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant. 2001;16(11):2158–65.

118. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359–64.

119. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebocontrolled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857–63.

120. Stefoni S, Mosconi G, La Manna G, et al. Lowdosage ibopamine treatment in progressive renal failure: a long-term multicentre trial. Am J Nephrol. 1996;16(6):489–99.

121. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42(2):452–8.

122. Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013;24(5):842–52.

123. Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol. 1999;10(5): 997–1006.

124. Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97(6):1117–29.

125. Kim JY, Steingroever J, Lee KH, et al. Clinical interventions and all-cause mortality of patients with chronic kidney disease: an umbrella systematic review of meta-analyses. J Clin Med. 2020;9(2):394.

126. Grams ME, Sang Y, Ballew SH, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol. 2019;30(9):1746–55.

127. Greene T, Ying J, Vonesh EF, et al. Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation. J Am Soc Nephrol. 2019;30(9):1756–69.

128. Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735–45.

129. Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84–104.